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Background. Few data are available on quarterly 11.25mg GnRH analog treatment in central precocious puberty (CPP). Aim.T o
assess the eﬃcacy of triptorelin 11.25mg in children with CPP. Patients. 17 patients (16 females) with CPP (7.9 ± 0.9 years) were
treatedwithtriptorelin11.25mg/90days.Methods.Gonadotropins,basal-,andGnRH-stimulatedpeak,gonadalsteroids,andpub-
ertal signs were assessed at preinclusion and at inclusion visit, 3 months, 6 months, and 12 months of treatment. Results.A t3 ,6 ,
and 12 months, all patients had suppressed LH peak (<3IU/L after GnRH stimulation), as well as prepubertal oestradiol levels.
MeanLHpeakvaluesafterGnRHtestsigniﬁcantlydecreasedfrom25.7±16.5IU/Latbaselineto0.9±0.5IU/LatM3(P<0.0001);
they did not signiﬁcantly changed at M6 and M12. Conclusions. Triptorelin 11.25mg/90 days eﬃciently suppressed the pituitary-
gonadal axis in children with CPP from ﬁrst administration.
1.Introduction
Central precocious puberty (CPP) refers to the development
of gonadotropin dependent onset of puberty before the age
of 8 years in girls and 9 years in boys [1]. CPP is caused
bytheprematurereactivationofthehypothalamic-pituitary-
gonadal-axis [1]. Gonadotropin stimulation of the gonads
induces the increase in sex steroid secretion that is responsi-
ble for the premature onset of somatic sexual characteristics
and is associated with growth spurt and accelerated skeletal
maturation that compromises adult height [1].
The GnRH analogs represent the treatment of choice for
CPP [2]. These drugs suppress gonadotropin secretion
through a desensitization and downregulation of GnRH
receptors, leading to reduction of gonadal steroids to prepu-
bertal levels [3].
The monthly depot formulations of GnRH analogs are
the main formulations used in the medical treatment of CPP
[1, 2]. It has been demonstrated that they provide a steady
release of drug [3] and improve signiﬁcantly the short as well
as the long-term outcome of children aﬀected by CPP with-
out relevant short-term or long-term side eﬀects [1, 2, 4].
Three months depot formulations of GnRH agonists are
now available and they are currently used in adults [5]. Since
CPP may require several years of treatment [2], the use of
three-month formulations would increase the eﬀectiveness
and the compliance with the therapy, but data on the use of
quarterly GnRH analogs in CPP remain scarce [6–10].2 The Scientiﬁc World Journal
This study assessed the eﬃcacy and the tolerability of
quarterly triptorelin 11.25mg in children with CPP.
2. Patientsand Methods
2.1. Patients. Children presented to our departments with
clinicalsignsofprecociouspuberty(n = 47)wereconsidered
for the study; 17 patients (16 girls and 1 boy, mean chrono-
logical age 7.9 ± 0.9 years) with idiopathic CPP met all the
requested clinical and hormonal criteria (see below) and
were recruited in the study.
The clinical and hormonal criteria were onset of pubertal
characteristicsdevelopmentbefore8yearsingirlsand9years
in boys, pubertal response of LH to standard GnRH test (LH
peak ≥ 7IU/L); diﬀerence between (Δ) bone age (BA) and
chronological age (CA) > 1 year, uterine length ≥ 36mm at
ultrasound measurement in girls, testosterone levels
> 0.5ng/mL in boys, negative MRimaging ofhypothalamus-
pituitary region [11].
2.2.StudyProtocol. Thepatientsweretreatedwithtriptorelin
11.25mg every 90 days. Pharmacokinetic studies in adults
demonstrated that the quarterly formulation of 11.25mg
triptorelin is steadily released over 91-day period [5].
Each dose of the drug was administered in outpatient
hospital setting by experienced nurses in paediatric endo-
crinology and the date of each administration was registered
on the clinical record of each child. Patients were actively
contacted some days before the injections to be sure on the
respect of administration protocol.
The study protocol based on preinclusion (ﬁrst visit and
endocrine testing), inclusion (M0: visit and ﬁrst triptorelin
injectionmadewithin1monthafterpre-inclusion),andfour
treatment visits in the occurrence of drug injection (M3,
M6, M9, and M12). At each visit, except M9 visit, pubertal
stage and hormonal parameters (basal and stimulated gona-
dotropins, 17β-estradiol or testosterone) were assessed. Aux-
ological parameters (height, weight, and growth velocity),
bone age, and uterine length (in girls) were taken at M0, M6,
and at M12 visits.
The primary endpoint of the trial was to assess the eﬃ-
cacyoftriptorelin11.25mginsuppressingGnRH-stimulated
LH peak at M3, M6, and M12. Optimal suppression was
deﬁned as a LH peak ≤ 3IU/L.
Secondary endpoints included suppression to prepuber-
tal levels of stimulated FSH after GnRH stimulation and
basalgonadalsteroids,aswellasvariationsofclinical(height,
height SD score, growth velocity, weight, and pubertal stage)
and radiological parameters (bone age). Assessment of trip-
torelin plasma levels was performed at M3, M6, and M12
before the drug injection.
2.3. Consent. Written informed consent was obtained from
both parents or by the liable parent or by the legal guardian,
whenapplicable;theassentwasalsoobtainedbythechildren,
when they were able to understand the explanation provided
by the endocrine paediatrician.
The study was approved by the Ethics Committee for
human investigations of the hospitals involved in the study.
2.4. Methods. Blood samples for measurements of biochem-
ical parameters were obtained in fasting state between 08.00
and 09.00. LH, FSH (baseline and GnRH stimulated (100μg
i.v.)), and 17β estradiol were assayed at time points M0, M3,
M6, and M12.
17β estradiol was assayed by commercial RIA method
(Estradiol US, Diagnostic System Laboratory, Webster TX
USA) with threshold of sensitivity of 2.0pg/mL, and inter-
and intraassay coeﬃcients of variation (CVs) were 9.4% and
7.5%, respectively. LH and FSH were assayed by commercial
microparticleenzymeimmunoassaymethod(AXsymAbbott
LH and FSH, Abbott Park, USA) with threshold of sensitivity
of 0.1IU/L for both hormones. For LH, inter- and intraassay
CVs were 7.3% and 5.1%, respectively. For FSH, inter- and
intraassay CVs were 6.4% and 4.9%, respectively. All endo-
crine assays were carried out at in independent laboratory
(Exacta Laboratory, Verona Italy) blinded to the treatment
regimen.
Triptorelin residual plasma levels were assessed by RIA
methods. The samples were collected at M3, M6, and M12
just before the injection.
Pubertal development was assessed according to Tanner
and Whitehouse [12]. Standing heights were measured with
a wall-mounted stadiometer. Heights were expressed as real
measured value or as SDS. The height SD score for the chro-
nological age was obtained from the tables of Tanner and
Whitehouse [12]. Midparental heights were adjusted for
thefemale([father’sheight+mother’sheight]/2−6.5cm)or
male ([father’s height+mother’s height]/2+6.5cm).
Bone age was determined using X-rays of the nondomi-
nant hand and wrist and estimated by the Greulich and Pyle
method[13].Predictedadultheightwascalculatedaccording
to the tables of Bayley and Pinneau [14].
Body mass index (BMI) was calculated according to the
formula:weight(kg)/height(m2),andBMISDscorewascal-
culated according to age and sex [15].
2.5. Statistical Analysis. Results are expressed as mean ± SD.
Analysisofvariancewasusedtocomparetheon-studyresults
with baseline values. A “P” value less than 0.05 was consid-
ered to be signiﬁcant in all instances. Statistical analyses were
carried out using the SPSS for Windows software program.
3. Results
3.1. Clinical and Radiological Features at Inclusion and during
Followup. Clinical features are reported in Table 1.H e i g h t
increased during the study period, but growth velocity (cm/
year) decreased to prepubertal values. Mean bone age pro-
gressed 11 months, predicted adult height increased, and
resulted close to midparental height at M12 (Table 1). The
BMI, as absolute values or SDS, unchanged (Table 1). Breast
development (B stage) as well as uterus length decreased
from M0 (2.7 ± 0.8, 45.7 ± 7.8 mm; resp.) to M12 [2.1 ± 0.8The Scientiﬁc World Journal 3
Table 1: Clinical data at the beginning of GnRH analog treatment
(M0) and after 12 months of quarterly triptorelin 11.25mg (M12).
M0 M12
Bone age, years 9.8 ±1.21 0 .7 ±1.1
Height, cm 132.7 ±7.8 139.1 ±8.6
◦
Height, SDS∗ −0.4 ±1.3 −0.3 ±0.9
Growth velocity, cm/year 11.0 ±4.94 .9 ±2.1
◦◦
Predicted adult height, cm 156.3 ±9.6 160.8 ±6.5
Predicted adult Height, SDS −0.7 ±1.5 −0.2 ±1.1
Body mass index, kg/m2 18.0 ±2.51 8 .6 ±2.4
Body mass index, SDS 2.8 ±2.72 .7 ±2.0
Midparental height, cm 161.0 ±4.5
Midparental height, SDS −0.2 ±0.8
∗SDS for bone age; ◦P<0.02 versus M0; ◦◦P<0.001 versus M0.
(P = 0.0001 versus M0), 35.3 ± 5.1( P = 0.0002 versus M0),
resp.]. Testicular volume did not change in the single boy.
3.2. LH, FSH, and Gonadal Steroids at Baseline and during
Treatment. Endocrine data at inclusion and during followup
are reported in Table 2. A signiﬁcant decrease of both basal
and peak LH values was found from baseline to M3 (P<
0.0001); thereafter the hormone values did not signiﬁcantly
changes (Table 2).
All the patients (100%) showed LH peaks at M3, M6,
and M12 below the cutoﬀ for optimal suppression (Table 2).
All the girls (100%) have suppressed levels of estradiol
(<70pmol/L) at M3, M6, and M12 (Table 2). Testosterone
in the single boy decreased from pubertal (baseline:
12.8nmol/L) to prepubertal values during followup (M12:
0.3nmol/L).
Basal and peak FSH levels decreased signiﬁcantly at M3
(P<0.0001) compared to the start of treatment and did not
changed thereafter (Table 2).
3.3. Residual Plasma Levels of Triptorelin. Serum triptorelin
levels were detectable in all the patients during followup
(M3: 84.0 ± 1.0pg/mL; M6: 64.0 ± 5.0pg/mL; M12: 42.0 ±
2.0pg/mL).
3.4. Tolerance. The drug was well tolerated. No patient with-
drew from the study because of adverse events. The possible
related side eﬀects during treatment were headache (22%)
and ﬂushes (1%). Three girls reported light vaginal bleeding





least in Europe [1, 2].
Quarterly and yearly depot formulations of GnRH
analogs are now available, having potential advantages in
improving compliance and the quality of life of children
under treatment [6–8, 16–20].
The eﬃcacy of quarterly preparations in adult clinical
setting has been well documented [5, 21, 22], but the stud-
ies evaluating these new formulations in CPP remain scarce
[6–10,16–18].Thus,weassessedtriptorelin11.25mgadmin-
istered every 90 days in suppressing gonadotropin secretion
in patients with CPP.
In this study, triptorelin 11.25mg signiﬁcantly reduced
LH values at M3 in comparison with baseline levels and all
peakswerebelowthechosencutoﬀvaluefromﬁrsttreatment
cycle. Optimal LH suppression was maintained up to M12
without signiﬁcant variations during followup, despite resid-
ual triptorelin levels reduced below the reported therapeutic
range[3],suggestingthatevenlowserumlevelsoftheagonist
is able to desensitize LH secretion. FSH and gonadal steroids
levels also decreased to prepubertal values, conﬁrming the
suppression of pituitary-gonadal axis. Clinical and imaging
data were in agreement with a drug-induced prepubertal
hormonal milieu, but longer followup is needed to give
sound conclusions on the eﬀectiveness of improving adult
height.
On biochemical point of view, our data were better than
those reported in previous studies with triptorelin 11.25.
Mart´ ınez-Aguayoetal.[8]treated19patientswiththisform-
ulation and found an adequate LH suppression in 90% at 3-
month of treatment. The 100% of suppression was achieved
only from 6 to 24 months [8]. Carel et al. [7]t e s t e dq u a rt e r l y
triptorelin in 52 girls with CPP; 85% showed LH peak below
their cutoﬀ value (3IU/L) after the ﬁrst drug dose and 97%
after the second dose. The better suppression of LH peak we
found from the ﬁrst drug administration may be due to the
strict protocol rules and the administrations made by expe-
rienced nurses. At this regard, a subset of Carel’s population,
which excluded patients with major protocol violations, was
fully suppressed at both 3 and 6 months of therapy [7]. In
the present study, the 100% triptorelin eﬃcacy would be
conﬁrmed even considering a very restrictive value of 2IU/L
as cutoﬀ for LH peak after GnRH stimulation test.
Regarding the other quarterly GnRH analogs, Carel et al.
[6]evaluatedleuprorelin11.25mginagroupof44girls:93%
of the patients had suppressed LH peak (cutoﬀ value 3IU/L)
after 3 months and 98% after 6 months of therapy. Never-
theless,themost appropriate dose ofleuprorelin totreatCPP
remains a debated issue. Badaru et al. [9]c o m p a r e dl e u p r o -
relin 3.75mg and 7.5mg monthly to the 11.25mg/3 months.
They found higher stimulated LH and FSH values with the
3.75mg/monthly and 11.25mg/3 months compared with
7.5mg/month, suggesting that the latter compound was
more eﬀective in suppressing the gonadotropins, although
nodiﬀerenceinsexsteroidlevelswerefound[9].Mericqetal.
[10] compared, in an open 1-year study, three diﬀerent doses
of leuprorelin: 7.5mg/monthly, 11.25/3 months, and 22.5/3
months. LH was suppressed in all the patients on 22.5mg/3
months, in all patients on 7.5/mg monthly by 9 months, and
in all patients on 11.25mg by 12 months. Recently, Fuld et
al. [23] compared monthly (7.5mg) and quarterly (11.25mg
and 22.5mg) depot formulations of leuprolide acetate in
the treatment of CPP. Mean stimulated LH and FSH levels4 The Scientiﬁc World Journal
Table 2: Biochemical data at baseline and 3, 6, and 12 months of quarterly triptorelin 11.25mg.
baseline 3 months 6 months 12 months
Basal LH, IU/L 1.9 ±1.60 .3 ±0.20 .4 ±0.40 .4 ±0.2
Peak LH, IU/L 25.7 ±16.50 .9 ±0.51 .0 ±0.51 .0 ±0.5
Peak LH < 3IU/L — 17/17 17/17 17/17
Basal FSH, IU/L 4.1 ±2.20 .9 ±0.51 .1 ±0.51 .5 ±0.8
Peak FSH, IU/L 11.7 ±4.71 .3 ±0.61 .3 ±0.61 .9 ±0.9
17β estradiol, pmol/L◦ 58.0 ±45.53 0 .8 ±7.72 7 .8 ±12.13 4 .1 ±12.1
17β estradiol < 70pmol/L◦ 11/16 16/16 16/16 16/16
◦data related to the 16 girls enrolled in the study. ◦Peak < 2IU/L 17/47 a M3, M6, M12.
Table 3: Eﬃcacy of LH peak suppression of long-acting GnRH analogs in CPP (short- and medium-term studies in de novo-treated child-
ren).
Sex Patients with optimal LH suppression, %
Author GnRH analog F, n M, n Cutoﬀ LH
peak, IU/L 3 months 6 months 9 months 12 months
Carel et al. [6] Leuprorelin 11.25mg 40 4 3.0 93.0 98.0 — —
Meriq et al. [16] Leuprorelin 11.25mg 10 1 3.0 — — — 88◦
Carel et al. [7] Triptorelin 11.25mg 54 10 3.0 85.0(97∧) 97(97∧) — 95(97∧)
Mart´ ınez-Aguayo
et al. [8] Triptorelin 11.25mg 19 1 3.0 90.0 100 100 100§
Trueman et al. [17] Goserelin 10.8mg 23 6 1.7 67.0 — — —
Isaac et al. [18] Goserelin 10.8mg 23 5 2.0 — — — 81∗
Lewis and Eugster
[19] Histrelin 50-mg 20 — 4.0 100 100 100 100◦◦
Present study Triptorelin 11.25mg 16 — 3.0 100∧∧ 100∧∧ 100∧∧ 100∧∧
◦data at 18 months of leuprorelin administration.
∧data in peer-protocol population (n = 37 patients who had received all doses of triptorelin 11.25 and without no major protocol violation).
§LH peak below 3.0IU/L was documented at 15, 18, and 21 months of followup. At month 24, 1 patient showed a leak peak at 3.0IU/L.
∗20/28 (71%) required treatment injections at 6–10 weekly intervals.
◦◦data were conﬁrmed in the 12–24 months of followup [20].
∧∧using the lower cutoﬀ value of 2.0IU/L [18], the percentage of patients with optimal suppression did not change.
during treatment were higher in the low-dose 11.25-mg 3-
m o n t hg r o u pa n dm o r eL Hl e v e l sa b o v ec u t o ﬀ (4IU/L) were
observed in comparison with the other two dose groups.
However, no diﬀerences in estradiol levels, growth velocity,
or bone age progression were observed in the three groups
[23]. The authors concluded that all leuprolide acetate for-
mulations determined prompt and eﬀective suppression of
puberty, but higher dosing may be required for multi-
monthly preparation in some circumstances [23]. Albeit de-
ﬁnitive conclusions about the eﬀectiveness of diﬀerent leu-
prorelin doses in CPP require additional comparative studies
and long-term evaluation, the lesser suppression reported in
patients treated with lower doses [9, 23, 24] may indicate
that the less biological activity of leuprorelin [3] may possi-
bly worsen long-term outcome when administered at the
minimal doses [9, 24]. At this regard, Massart et al. [25]r e -
ported that ﬁnal height was signiﬁcantly lower of about 0.6
SDS in girls treated with monthly leuprorelin 3.75mg in
comparison with those treated with monthly triptorelin
3.75mg (P<0.05).
Regarding goserelin, Isaac et al. [18] compared the
10.8mg formulation administered every 9–12 weeks with
that of 3.6mg given monthly over a 12-month period. They
found that 71% of the patients treated with quarterly formu-
lations and 44% of those treated with monthly formulation
had inadequate clinical and/or biological suppression [18].
They concluded that patients treated with goserelin depot
may require an increase in injection frequency, especially
those treated with quarterly formulation [18]. Trueman et al.
[17] also assessed quarterly goserelin 10.8mg in CPP and
found that 2% of their patients had inadequate suppression
at 8-week followup. The percentage rose to 13% at 12 weeks,
leading to the conclusion that some patients treated with
goserelinmayrequireincreasedinjectionfrequencytoobtain
adequate suppression [17].
Recently, very long delivery system was used to treat CPP
in USA, as subcutaneous histrelin implants (50mg/year, rel-
easing 60μg/daily) [19, 20]. Two-year followup demonstrat-
ed eﬀectiveness and safety of this formulation, but larger
samples and long-term outcome should be evaluated [19,
20].
Overall,thenewformulationsofGnRHanalogswerewell
tolerated, as we found in the present report. Sterile abscess
formation, reported as a complication of leuprolide acetateThe Scientiﬁc World Journal 5
(15mg monthly) and histrelin acetate (50-mg yearly) [26],
hasbeennotobservedwithtriptorelindepotinthisandother
reports [7, 8, 16, 26].
In conclusion, the present study showed that quarterly
triptorelin 11.25mg is eﬀective in suppressing pituitary-gon-
adal axis during the ﬁrst year of treatment, when strict rules
ofadministrationarewarranted.Comparingourresultswith
published data (Table 3), the eﬃcacy of triptorelin 11.25mg
seems to be better from ﬁrst treatment cycle than that of
other quarterly GnRH analogs administered at similar doses
(Table 3). Direct short- and long-term comparative trials
among the various GnRH analog and diﬀerent formulations
using homogeneous criteria to deﬁne cutoﬀ level for ade-
quate suppression would be performed to give better indica-
tions for clinical practice. In addition, more information on
the relationship between on-treatment measures of gona-
dotropin suppression and ﬁnal outcomes is needed [2].
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